Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Zonder, J. A., Richter, J., Bumma, N., Brayer, J., Hoffman, J. E., Bensinger, W. I., Wu, K. L., Xu, L., Chokshi, D., Boyapati, A., Sharma, M., Rodriguez Lorenc, K., Kroog, G. S., Dhodapkar, M. V., Lentzsch, S., Cooper, D., & Jagannath, S. (2021). Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 138(Supplement 1), 160–160. https://doi.org/10.1182/blood-2021-144921

Authors:

Jeffrey A. Zonder

Joshua Richter

Naresh Bumma

Jason Brayer

James E. Hoffman

William Bensinger

Ka Lung Wu

Linzhi Xu

Dhruti Chokshi

Anita Boyapati

Manish Sharma